YOLFTbeta
33

Prestige Biologics Co. Ltd.

334970 · KQ · Healthcare / Pharmaceuticals

1,165.00KRW-19.00 (-1.60%)

Price History

Full chart

Market Stats

Previous Close1,184.00
Open1,151.00
Day Range1,126.00 – 1,197.00
52-Week Range1,230.00 – 3,850.00
Volume366.91K
Market Cap111.50B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
50-Day Avg1,688.28
200-Day Avg2,260.72

About

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd. was formerly known as PrestigeBio Pharmaceuticals and changed its name to Prestige Biologics Co., Ltd. in October 2019. The company was founded in 2015 and is based in Cheongju-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryPharmaceuticals
  • Employees0
  • Headquarters197, Osongsaengmyeong 1-ro, Cheongju-Si, South Korea, 28161, Korea
  • Websitehttp://pbpharma.co.kr

Financials

Income Statement

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Revenue0184.75M03.23B15.57M2.17B12.53B
Growth (%)---100.00%--99.52%+13834.76%+477.83%
Cost of Revenue000872.81M11.96M10.86B28.22B
Gross Profit0184.75M02.35B3.60M-8.69B-15.69B
Gross Margin-100.00%-72.95%23.13%-400.48%-125.15%
Operating Expense15.79B12.64B22.60B29.19B37.28B24.74B18.00B
Operating Income-15.79B-12.45B-22.60B-26.84B-37.28B-33.43B-33.68B
Operating Margin--6740.96%--831.68%-239483.49%-1541.23%-268.74%
EBITDA-----37.85B-6.37B-5.65B
EBITDA Margin-----243168.69%-293.88%-45.10%
Net Income-26.91B-22.06B-31.03B-39.38B-49.72B-29.37B-27.47B
Net Income Margin--11938.78%--1220.33%-319406.80%-1354.23%-219.17%
R&D--18.36B25.10B30.97B9.30B2.59B
R&D as % of Total Revenue---777.76%198962.59%428.80%20.65%
Interest Expense002.90B763.51M3.93B11.77B8.73B
Interest Expense % of Total Revenue-0.00%-23.66%25239.05%542.57%69.69%

Balance Sheet

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Assets73.17B72.10B50.23B206.77B258.08B289.41B270.29B
Total Liabilities72.35B43.25B51.63B99.94B140.47B217.73B135.08B
Total Equity822.18M28.85B-1.40B106.83B117.61B71.68B135.20B
Cash--4.24B1.86M477.57K29.51B1.58B
Total Debt--9.23B----
Net Debt--23.36B41.09B103.12B143.46B89.87B

Cash Flow

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow-10.39B-12.30B-13.37B-25.75B-34.19B-8.35B-18.31B
Investing Cash Flow-40.04B-3.55B7.16B-97.91B-83.67B-7.93B-
Financing Cash Flow59.08B9.05B-1.18B156.31B96.46B344.50M-
Capital Expenditure24.89B8.38B2.97B97.39B84.79B8.64B5.66B
Free Cash Flow---16.42B-123.76B-118.91B-16.98B-23.96B
FCF to OCF--122.83%480.63%347.80%203.50%130.89%

Earnings

Report DateMar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------
EPS Actual-22.17-440.40-65.94-310.70-241.47-356.23-383.92-29.44-151.78-85.46-170.9530.76-257.52-103.95-179.92-96.365.63-166.30-106.53-188.41-197.51
Surprise---------------------
Timing---------------------

Key Statistics & Ratios

Market Cap111.50B
Enterprise Value190.48B
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.53
Price / Book0.99
Revenue (TTM)2.83B
Gross Profit (TTM)2.35B
EBITDA-28.31B
Profit Margin0.00%
Operating Margin-1246.98%
Return on Equity-3132.06%
Return on Assets-10.65%
Shares Outstanding0
Shares Float20.26M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%